NTHI
NASDAQNeOnc Technologies Holdings Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News25/Ratings0
News · 26 weeks56+200%
2025-10-262026-04-19
Mix3190d
- SEC Filings19(61%)
- Insider6(19%)
- Other3(10%)
- Earnings2(6%)
- Leadership1(3%)
Latest news
25 items- INSIDERPresident Heshmatpour Amir F bought $49,000 worth of shares (10,000 units at $4.90), increasing direct ownership by 0.33% to 3,052,000 units (SEC Form 4)4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
- SECSEC Form EFFECT filed by NeOnc Technologies Holdings Inc.EFFECT - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
- SECNeOnc Technologies Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
- SECSEC Form 424B5 filed by NeOnc Technologies Holdings Inc.424B5 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
- PRNeOnc Technologies Holdings, Inc. Announces ~ $300,000 in Insider Purchases of NTHI Stock by Chairman and CEO; Company Provides Context on 2025 Financial ResultsInsider buying indicates management's conviction in undervalued shares ahead of multiple near-term catalysts: NEO100: interim data readout - expected within ~4 months NEO212: expects Type B End-of-Phase FDA meeting to align on a potential pivotal, registrational Phase 2 study - within the next 4 weeks CALABASAS, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. ("NTHI" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that Chairman and CEO Amir Heshmatpour has purchased approximately $300,000 worth of NTHI stock in the last week, demonstrating managem
- INSIDERSEC Form 4 filed by Suh, David Jr.4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
- INSIDERSEC Form 3 filed by new insider Suh, David Jr.3 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
- SECSEC Form S-3 filed by NeOnc Technologies Holdings Inc.S-3 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
- SECNeOnc Technologies Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
- SECSEC Form 424B5 filed by NeOnc Technologies Holdings Inc.424B5 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
- INSIDERSEC Form 4 filed by Heshmatpour Amir F4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
- SECSEC Form EFFECT filed by NeOnc Technologies Holdings Inc.EFFECT - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
- INSIDERSEC Form 4 filed by Heshmatpour Amir F4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
- INSIDERSEC Form 4 filed by Heshmatpour Amir F4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
- SECNeOnc Technologies Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
- SECSEC Form S-3 filed by NeOnc Technologies Holdings Inc.S-3 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
- PRNeOnc Provides Business Update and Reports Q4 2025 Financial ResultsCALABASAS, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced financial results for the quarter and year ended December 31, 2025, and provided an update on recent operational achievements and upcoming milestones. Amir Heshmatpour, Chief Executive Officer, Executive Chairman, and President, commented: "Q4 2025 and early 2026 marked important inflection points for NeOnc. We completed NEO212's Phase 1 dose escalation and established a recommended Phase 2 dose of 610 mg, with early sig
- SECSEC Form 10-K filed by NeOnc Technologies Holdings Inc.10-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
- SECNeOnc Technologies Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
- PRNeOnc Technologies Appoints David Choi as Chief Accounting OfficerCALABASAS, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, has appointed David Choi as Chief Accounting Officer. In this role, Mr. Choi is responsible for overseeing the Company's accounting, financial reporting, internal controls, and corporate governance functions as NeOnc advances its clinical-stage biotechnology platform and expands its global operations. "David's extensive expertise in technical accounting and financial reporting for public companies comes at a pivotal time for NeOnc," said
- SECNeOnc Technologies Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
- SECNeOnc Technologies Holdings Inc. filed SEC Form 8-K: Other Events8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
- PRNeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ETCALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced data from the dose-escalation portion of its Phase 1/2 clinical trial for NEO212, the Company's novel oral bio-conjugated therapy and will host a conference call to discuss the data today at 9:00am ET. NeOnc has formally notified the FDA that the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial has reached Maximum Tolerated Dose (MTD) at Cohort 5 (810 mg, Days 1–5, 28-day cycle) following a second
- SECNeOnc Technologies Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
- SECNeOnc Technologies Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)